Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solbinsiran in Mixed Dyslipidemia
NCT05256654Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of solbinsiran in mixed dyslipidemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change From Baseline for Apolipoprotein B at Day 180. Started Jul 2022; status: completed.
02
Drugs
solbinsiran
03
Conditions
mixed dyslipidemia
Beyond the preview
Go deeper on NCT05256654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256654.